Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in RAI-refractory differentiated thyroid cancer
NCT00984282Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of sorafenib in differentiated thyroid cancer (DTC), sponsored by Bayer. Started Oct 2009; status: completed.
02
Drugs
sorafenib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT00984282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984282.